Clinical Trial Update: Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating intravitreal adalimumab for refractory diabetic retinopathy, choroidal neovascularization, or uveitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Retinopathy
• Uveitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Rafic Hariri University Hospital | Conditions: Uveitis, Diabetic Retinopathy | Phase 1 | Status: UNKNOWN